Next generation discovery.
The Human Interactome Project is still in progress, the last round is completed in 2014 after more then 10 years of research (Rolland et al., 2014). The experimental technologies, what they use, are resource-intensive and lack parallelism to establish a static blueprint of the interactome. Actome mission is to add dynamics, even vastly parallel dynamics.
Interactomics deals with the interactome. In cells, the proteins, nucleic acids etc. are connected by physical interactions, they form the ever changing molecular interaction networks establishing the dynamics of the life. Most commonly, interactome refers to protein–protein interaction (PPI) networks but the protein–DNA interactome, formed by transcription factors, chromatin regulatory proteins, and their target genes also has great interest. The detailed understanding of the interactome is the ultimate aim of life sciences providing insights of health and disease,
Genome-wide association studies, ignited by the Human Genome Project success, have identified over 140 000 mutations with at least one associated genetic disease. Despite of these fundamental proceedings, the connections between the mutations and the disease or normal remain elusive, especially in the context of multigenic traits and many disease, especially cancer.
Systems pathology based drug discovery using an ultrahigh-parallel emulsion coupling assay both in the number of screened compounds and at the same time, in number of PPI targets.
Or...characterizing circulating tumor cell populations with single-cell resolution in a multiomics fashion and delivering a homogeneous, single-reaction based, high-throughput, genomic, transcriptomic, proteomic, epigenomic and interactomic profiling tech?
Emulsion coupling is an enabling proteomics/interactomics technology with no close competitor techs in sight. Emulsion coupling, actually, is a diversified portfolio of many cutting-edge technological solutions, and it is based on a very active research hub involving partners from many countries. The scientific and commercial potential of these technologies is best exploited through partnering. Do you have a proteomics/interactomics problem, research direction? We offer, co-development in various licensing frameworks, including free licenses.
The concept of emulsion coupling technology. Specific antibodies labeled with unique nucleic acids (UNALs) are used to reveal the co-localisation information of interacting proteins (a) UNAL-antibodies are in equilibrium binding on their targets, (b-c) compartment based PCR dimerisation of the unique antibody UNALs, (d) dimers are detected using ddPCR technology. Letters/colors indicate dimer compositions. Patent pending (WO 2016083793 A1).